Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of basal insulin peglispro and insulin glargine in terms of endogenous glucose production, glucose disposal rate and lipolysis in patients with type 1 diabetes: A randomised, open-label, four-period crossover study

Trial Profile

Comparison of basal insulin peglispro and insulin glargine in terms of endogenous glucose production, glucose disposal rate and lipolysis in patients with type 1 diabetes: A randomised, open-label, four-period crossover study

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Insulin peglispro (Primary) ; Insulin glargine
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 20 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top